On October 21, 10x Genomics, Inc. and Prognosys Biosciences, Inc. filed a complaint for patent infringement against Illumina, ...
At the booth of Gilead Sciences, Lenacapavir, to be used as the world's only twice-yearly, long-acting injectable for HIV ...
Pillar Biosciences, Inc., the leader in Decision Medicine(TM), announced its participation in the 2025 Association for Molecular Pathology (AMP) Annual Meeting in Boston, MA. The company and ...
The Print on MSN
Doctors still treat heart disease with trial and error. This start-up wants to change that
India-specific database of Coronary Artery Diseases will help identify if a person has a risk factor of developing heart ...
Google recently launched an artificial intelligence tool called DeepSomatic, which is designed to detect genetic mutations ...
Illumina’s revenue was flat for the third quarter as the sequencing giant continues to deal with headwinds from a China sales ...
Biotech company 10x Genomics filed two lawsuits against rival Illumina in Delaware federal court on Tuesday, accusing ...
Genomics has administered a double dose of litigation to Illumina, joining with separate partners in a pair of federal lawsuits accusing the sequencing giant of infringing on nine patents related to ...
This week, the Broad Institute gene-sequencing lab said it read infants’ DNA genomes in less than four hours, cutting an hour off the previous Guinness World Record. The point for investors is that ...
Having examined the options trading patterns of Illumina, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance Trading volume ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback